Purple Biotech to Present Innovations at Investment Conference
Purple Biotech Ltd. (NASDAQ/TASE: PPBT) is making significant strides in the biotechnology industry as a clinical-stage company focused on developing innovative therapies to combat tumor immune evasion and drug resistance. The executive team is thrilled to share that they will be participating in the esteemed H.C. Wainwright 26th Annual Global Investment Conference. During this event, they will host a virtual Fireside Chat and hold one-on-one meetings with institutional investors.
Conference Details
The conference is set to take place from September 9-11. Purple Biotech's virtual Fireside Chat will be available for on-demand viewing starting at 7:00 AM ET on September 9. Those interested can access the presentation in the Investor section of Purple Biotech’s website, where it will remain available for 30 days, providing ample opportunity to gain insights into the company's innovative strategies.
Investor Engagement Opportunities
For investors eager to participate in the Fireside Chat, a simple registration link is provided to secure their spot in this informative session. Furthermore, CEO Gil Efron will be available for personalized one-on-one meetings with investors at the Lotte New York Palace Hotel, showcasing Purple Biotech's commitment to open communication and collaboration with its stakeholders.
Exploring Purple Biotech’s Innovative Pipeline
Purple Biotech is at the forefront of oncology, boasting a robust pipeline that includes promising candidates such as CM24, NT219, and IM1240. Each of these candidates is designed to tackle significant challenges in cancer treatment.
CM24: Advancing Cancer Treatment
CM24 is a humanized monoclonal antibody that specifically targets CEACAM1, a protein crucial for tumor immune evasion and survival. Its innovative design aims to disrupt various pathways that tumors utilize to thrive. Currently, CM24 is undergoing a Phase 2 study for the treatment of pancreatic ductal adenocarcinoma (PDAC) in combination with anti-PD-1 checkpoint inhibitors. This effort includes a key partnership with Bristol Myers Squibb, highlighting Purple Biotech’s commitment to collaborative advancements in cancer care.
Progress with NT219 and IM1240
Another exciting development is NT219, a novel small molecule that inhibits both IRS1/2 and STAT3. After successful Phase 1 trials, it is moving forward for further investigation, particularly regarding its anti-tumor properties in recurrent and metastatic head and neck cancers. Additionally, IM1240 represents Purple Biotech’s cutting-edge work with its tri-specific antibody that targets the antigen 5T4, which is closely associated with various solid tumors.
The Company’s Vision and Future Directions
Purple Biotech is committed to harnessing the immune system's potential to more effectively combat cancers. Their innovative development platform focuses on creating therapies that activate both innate and adaptive immune responses, a comprehensive approach that could transform patient outcomes.
Headquartered in Rehovot, Israel, Purple Biotech is dedicated to pushing the limits of what is achievable in oncology. For more information about their ongoing projects and developmental progress, interested parties can visit their official website.
Frequently Asked Questions
What is the focus of Purple Biotech?
Purple Biotech is focused on developing first-in-class therapies aimed at overcoming tumor immune evasion and drug resistance.
When is the H.C. Wainwright Investment Conference?
The conference is scheduled for September 9-11, with a virtual Fireside Chat available for on-demand viewing starting on September 9 at 7:00 AM ET.
What are the main products under development by Purple Biotech?
The key products in development include CM24, NT219, and IM1240, which focus on innovative strategies for cancer treatment.
Where is Purple Biotech located?
The company is headquartered in Rehovot, Israel.
How can investors learn more about Purple Biotech's developments?
Investors can visit the company's official website to find information about ongoing projects and clinical advancements.
